ArticleGastro hep advances2026
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Pain Management in Chronic Pancreatitis: A Real-World Cohort Study.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Chronic pancreatitis (CP) is a debilitating inflammatory condition characterized by irreversible glandular destruction and intractable pain. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated anti-inflammatory properties in preclinical models, yet their impact on clinical outcomes in CP remains unexplored. Methods: In this retrospective cohort study, adult patients (≥18 years) with CP were identified from the TriNetX US Collaborative Network. Patients were stratified into the following two cohorts: those prescribed GLP-1 RAs and a control group without such prescriptions. 1:1 propensity score matching was performed to balance cohorts for age, sex, race, and key comorbidities. Primary outcomes were assessed over a 3-year observation period. Hazard ratios (HRs) were estimated using Kaplan-Meier survival analysis. Results: After matching, 10,625 patients were included in each cohort (mean age 59.6 ± 13.1 years; 53.7% female). GLP-1 RA users had a 41% lower hazard of initiating chronic opioids (HR 0.59, 95% confidence interval [CI] 0.52-0.67; Conclusion: GLP-1 RA use was associated with a substantial reduction in new opioid prescriptions and invasive pancreatic interventions in CP. These findings suggest that GLP-1 RAs may be helpful in symptom control and multidisciplinary management of selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.